{"schema_version":"secwatch.filing_event.v1","accession":"0001087294-25-000023","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2025-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.763613+00:00","generated_at":"2026-05-16T17:14:35.267851+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Cumberland amends credit line: reduces revolver to $15M, extends maturity to Oct 2027","bullets":["Principal available reduced to $15M (from $20M); right to request additional $10M (up from $5M).","Maturity extended to October 1, 2027; interest rate is Benchmark Term SOFR + 2.75%.","New financial covenant: Minimum Fixed Charge Coverage Ratio of 1.75x, replacing Maximum Funded Debt Ratio.","Borrowing Base Requirements made permanent; company paid $15,000 amendment fee.","Collateral remains substantially all assets; credit line with Pinnacle Bank."],"urls":{"canonical":"https://secwatch.observer/filing/0001087294-25-000023","json":"https://secwatch.observer/filing/0001087294-25-000023.json","markdown":"https://secwatch.observer/filing/0001087294-25-000023.md","text":"https://secwatch.observer/filing/0001087294-25-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/0001087294-25-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/cpix-20251118.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:14:35.267851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76670528715e18a6bdf408d7b612ab6005bf3a8f","claim":"CUMBERLAND PHARMACEUTICALS INC incurred revolving credit of up to $15 million with Pinnacle Bank at Benchmark Term SOFR plus 2.75% maturing October 1, 2027.","evidence_excerpt":"The Amendment provides for a principal available for borrowing of up to $15 million.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1087294/000108729425000023/0001087294-25-000023-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"up to $15 million"},{"label":"Counterparty","value":"Pinnacle Bank"},{"label":"Rate","value":"Benchmark Term SOFR plus 2.75%"},{"label":"Maturity","value":"October 1, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}